Skip Navigation Links.
Collapse Public HomePublic Home
Collapse DownloadsDownloads
Public documents
Collapse ContactContact
Contacts
Collapse Trial StaffTrial Staff
Trial Staff Login
 
   
 
















 

TWICS - Theophylline with Inhaled CorticoSteroids

Chronic Obstructive Pulmonary Disease (COPD) is a progressive lung disease affecting approximately 3 million people in the UK.  It is the fifth leading cause of death in the UK and costs the NHS approximately £1 billion annually.  Exacerbations of COPD are associated with accelerated rate of lung function decline, reduced physical activity, reduced quality of life, increased mortality and increased risk of other illnesses such as acute myocardial infarction and stroke. 

Usual treatment for COPD is inhaled corticosteroids.  Small studies have shown that giving patients theophylline at a low dose can increase the sensitivity of their airway to the effects of inhaled corticosteroids – and thus make the inhaled corticosteroids work better. 

In the TWICS study, we aim to determine whether adding low dose oral theophylline to inhaled corticosteroid therapy in patients with COPD reduces the risk of exacerbation, is cost effective to the NHS, improves quality of life and lung function and reduces mortality.  To do this, we will compare the effects of low dose theophylline against the effects of a placebo ‘dummy treatment’, which looks like the genuine medicine but contains no active ingredient.

We will invite people with COPD to take part in our study.  If they agree, we will allocate them to receive low-dose theophylline or placebo for 12 months.  Half of the participants in the study will take low-dose theophylline and half of the participants will take placebo.  We aim to recruit 1424 people with COPD into our study.

We will follow-up study participants after 6 and 12 months to find out how they are getting on and whether they have had any exacerbations of their COPD.

The TWICS trial has recruited patients across the UK - and we have now reached our recruitment target.  Follow-up in the study will continue until September 2017.

A summary of the study can be found here.  You can read more about the study here

 

 


The Health Services Research Unit is funded by the Chief Scientists Office of the Scottish Government Health and Social Care Directorates